136 related articles for article (PubMed ID: 1517967)
1. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160.
Vasudevachari MB; Uffelman KW; Kovacs J; Yeh CK; Lane HC; Salzman NP
J Acquir Immune Defic Syndr (1988); 1992; 5(8):817-21. PubMed ID: 1517967
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
3. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
[TBL] [Abstract][Full Text] [Related]
4. Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial.
Archibald DW; Hebert CA; Sun D; Tacket CO
J Acquir Immune Defic Syndr (1988); 1990; 3(10):954-8. PubMed ID: 2204698
[TBL] [Abstract][Full Text] [Related]
5. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
6. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
Graham BS
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
[No Abstract] [Full Text] [Related]
8. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
9. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
10. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.
Haubrich RH; Takeda A; Koff W; Smith G; Ennis FA
J Infect Dis; 1992 Mar; 165(3):545-8. PubMed ID: 1538159
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
[TBL] [Abstract][Full Text] [Related]
13. Variation of secretory antibodies in parotid saliva to human immunodeficiency virus type 1 with HIV-1 disease stage.
Sun D; Archibald DW; Furth PA
AIDS Res Hum Retroviruses; 1990 Jul; 6(7):933-41. PubMed ID: 2117957
[TBL] [Abstract][Full Text] [Related]
14. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
[TBL] [Abstract][Full Text] [Related]
16. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Kliks S; Wright PF
J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
[TBL] [Abstract][Full Text] [Related]
17. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
18. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
Cooney EL; Collier AC; Greenberg PD; Coombs RW; Zarling J; Arditti DE; Hoffman MC; Hu SL; Corey L
Lancet; 1991 Mar; 337(8741):567-72. PubMed ID: 1671940
[TBL] [Abstract][Full Text] [Related]
19. Practical applications for saliva in perinatal HIV diagnosis.
Archibald DW; Farley JJ; Hebert CA; Hines SE; Nair P; Johnson JP
Ann N Y Acad Sci; 1993 Sep; 694():195-201. PubMed ID: 8215055
[No Abstract] [Full Text] [Related]
20. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]